Check Up Archive: May, 2012

Should pharma grow, shrink or what?

Comment icon 0 Comments
by Daniel R. Hoffman, Ph.D. What does it say about an industry when its leading competitors appear fundamentally at odds about whether they... Read more

FDA and ISMP working together help consumers prevent errors

Comment icon 0 Comments
by Michael R. Cohen, R.Ph. The U.S. Food and Drug Administration (FDA) and the organization I work for, the nonprofit Institute for Safe Medication... Read more

Your coverage may get much better under health reform

Comment icon 0 Comments
by Robert I. Field, J.D., Ph.D. What’s the point of health insurance if it doesn’t cover much? Many policies today are so skimpy... Read more

Upcoming chat: What to do about PSA testing

Comment icon 0 Comments
Earlier this month, an influential federal panel rejected PSA (prostate-specific antigen) screening for prostate cancer, stirring controversy... Read more

Why pharma lacks strategic perspective

Comment icon 0 Comments
by Daniel R. Hoffman, Ph.D. An article published last year addressed a factor generally associated with corporate failure and success. Although... Read more

Laundry packets tempting to children

Comment icon 0 Comments
by Michael R. Cohen, R.Ph. I don’t usually stray too far from medication-related topics for my blogs each week. However, something crossed... Read more

Health reform is good for business

Comment icon 0 Comments
by Robert Field, J.D., M.P.H., Ph.D. Big business could be the biggest loser if the Supreme Court overturns Obamacare. To be more precise... Read more

Pharma at the Rubicon

Comment icon 0 Comments
by Daniel R. Hoffman, Ph.D. One way of viewing the drug industry's current situation — underperforming the S&P 500 by more than... Read more